Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. (ANEB) priced its initial public offering on May 10, 2021 at $7.00 per share, within its $6.00–$8.00 range, raising $21M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $162.9M. Benchmark was lead-left underwriter. Olshan Frome Wolosky advised the company and Faegre Drinker advised the underwriters.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing treatments for cannabinoid overdose and substance addiction. Its lead candidate, ANEB-001, is intended to reverse the effects of THC overdose within an hour of administration.

Status

IPO

Ticker

ANEB

Exchange

Nasdaq Capital Market

Priced

May 10, 2021

IPO price

$7.00

Price range

$6.00–$8.00

Raised

$21M

Market cap at IPO price

$162.9M

First filed

Apr 1, 2021

Underwriters

Benchmark

Company counsel

Olshan Frome Wolosky

Underwriters' counsel

Faegre Drinker

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.